Tsai H K, Li S, Ng A K, Silver B, Stevenson M A, Mauch P M
Harvard Radiation Oncology Program, 75 Francis Street, Boston, MA 02115, USA.
Ann Oncol. 2007 Apr;18(4):672-8. doi: 10.1093/annonc/mdl468. Epub 2007 Jan 11.
Few large studies exist on the outcome of patients treated for stage I/II mucosa-associated lymphoid tissue (MALT) lymphoma.
We retrospectively reviewed the records of 77 patients consecutively treated for stage I (n = 66) or II (n = 11) MALT lymphoma at our institution. Progression-free survival (PFS), freedom from treatment failure (FFTF), and overall survival (OS) were calculated using the Kaplan-Meier method.
The median follow-up time was 61 months (range 2-177 months). Fifty-two patients (68%) received local radiation therapy (RT) alone, 17 (22%) had surgery followed by adjuvant RT, five (6%) had surgery alone, two (3%) had surgery and chemotherapy, and one patient had chemotherapy alone. The median RT dose was 30 Gy (range 18-40 Gy). The 5-year PFS, FFTF, and OS rates were 76%, 78%, and 91%, respectively. The 5-year PFS (79% versus 50%; P = 0.002) and FFTF (81% versus 50%; P = 0.0004) rates were higher for patients who received RT as compared with patients who did not.
The prognosis following treatment of stage I/II MALT lymphoma is excellent. RT improves PFS and FFTF and has an important role in the curative treatment of patients with localized disease.
关于Ⅰ/Ⅱ期黏膜相关淋巴组织（MALT）淋巴瘤患者的治疗结局，大型研究较少。
我们回顾性分析了我院连续治疗的77例Ⅰ期（n = 66）或Ⅱ期（n = 11）MALT淋巴瘤患者的病历。采用Kaplan-Meier法计算无进展生存期（PFS）、无治疗失败生存期（FFTF）和总生存期（OS）。
中位随访时间为61个月（范围2 - 177个月）。52例患者（68%）仅接受局部放疗（RT），17例（22%）接受手术加辅助放疗，5例（6%）仅接受手术，2例（3%）接受手术及化疗，1例患者仅接受化疗。中位放疗剂量为30 Gy（范围18 - 40 Gy）。5年PFS、FFTF和OS率分别为76%、78%和91%。接受放疗的患者5年PFS（79%对50%；P = 0.002）和FFTF（81%对50%；P = 0.0004）率高于未接受放疗的患者。
Ⅰ/Ⅱ期MALT淋巴瘤治疗后的预后良好。放疗可改善PFS和FFTF，在局限性疾病患者的根治性治疗中具有重要作用。
